Drugs / IDO5 peptide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01219348 | Jun 2010 → Aug 2012 | non-small cell lung carcinoma | Inge Marie Svane | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01543464 | May 2012 → Sep 2016 | melanoma | Inge Marie Svane | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDO5 peptide | “Patients were treated with imiquimod ointment and subcutaneous vaccinations (100 μg IDO5 peptide, sequence ALLEIASCL, formulated in 900 μL Montanide).” PMID 24218513 ↗ Nov 20131“Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week” NCT01543464 ↗ |
| Action | Inhibit | “To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.” NCT01219348 ↗ |
| Modality | Vaccine | “To investigate targeting of indoleamine 2,3 dioxygenase (IDO) enzyme using a synthetic peptide vaccine administered to patients with metastatic non-small cell lung cancer (NSCLC).” PMID 24218513 ↗ Nov 2013 |
| Route | Subcutaneous | “subcutaneous vaccinations” PMID 24218513 ↗ Nov 2013 |